National Center for Health Research submitted a written public comment to the FDA docket that advised the agency on the kinds of research needed to ensure that non-opioid pain medications are safe and effective for chronic pain and patients can make informed choices. We point out that it would be unethical to conduct studies that compare these products to opioids in clinical trials.
Read More »Author: Caroline Bradford
STAT: In an unconventional process, FDA reverses a decades-old warning for hormone therapy
STAT News, Nov. 11, 2025: STAT News describes the diversity of views on the decision to remove black
box warnings for menopausal hormone therapy, but the HHS announcement and
description of hormone therapy benefits was more PR than science, says NCHR Dr.
Diana Zuckerman
Helio: HHS revises hormone therapy black box warning for menopause treatment
Healio, November 10, 2025: Healio.com reports Commissioner Makary and HHS Secretary RFK Jr. plans to eliminate black box warnings on menopause hormone therapy but they exaggerate hormone benefits say Drs. Diana Zuckerman, Barbara DePree and Nanette Santoro.
Read More »Inside Health Policy: FDA To Proceed With ‘Expert Panels’ Amid HRT Conflict Concerns
Inside Health Policy, November 10, 2025: Inside Health Policy describes controversy about FDA “Expert Panels” and quotes NCHR Diana Zuckerman on why these panels have conflicts of interest and eliminating menopausal hormone therapy black box warnings about cancer and heart disease is a mistake.
Read More »US to remove warnings from menopause hormone therapy
AFP News, November 11, 2025: France 24 explains FDA decision to delete most black box warnings for hormone therapy for menopause, despite controversies about the risks. NCHR’s Diana Zuckerman says warnings needed to be updated but hormones have serious risks and limited benefits.
Read More »